厄贝沙坦和氢氯噻嗪治疗原发性高血压的临床观察

目的:观察厄贝沙坦和氢氯噻嗪联合治疗原发性高血压的疗效及安全性。方法:56例轻中度原发性高血压患者,停药两周后,随机分为两组:联合治疗组(厄贝沙坦150mg/d及氢氯噻嗪12.5mg/d)。单药治疗组((厄贝沙坦150mg/d),每组28例,疗程8周。在治疗第1、2、4、8周末记录血压、心率及不良反应。结果:联合治疗组总有效率92.9%;单药治疗组总有效率78.5%,两组比较有统计学差异(p<0.01)。结论:厄贝沙坦和氢氯噻嗪联用能有效控制血压,用药简单、方便、不良反应少,是值得临床推广的联合降压方案。

Effect and safety of Irbesartan and Hydrochlorothiazide combination therapy on essential hypertension

Objective: Observe the curative effect and safety of Irbesartan and Hydrochlorothiazide when they are combined to treat essential hypertension.Methods: Two weeks after the medince is ceased, 56 less serious essential hypertension patients were divided into groups at random: the combination treatment group (Irbesartan,150mg/d and Hydrochlorothiazide,12.5mg/d ) and the single medince treatment group (Irbesartan,150mg/d). Each group has 28 patients and the course of treatment is 8 weeks. Blood pressure, heart rate(HR) and adverse reaction were recorded after treatment at the end of 1,2,4,8 weeks. Result: The rate of effectiveness of the combination treatment group reached 92.9%,while the single medince treatment group reached 78.5%. There was a significant difference between them in statistics (p<0.01). Conclusion: It is simple and convenient to control essential hypertension effectively by using Irbesartan and Hydrochlorothiazide together. And there is less adverse reactions. Therefore it is worthwhile to spread the method of reducing blood pressure in clinical practice.